Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Estimating Hospital-Related Deaths Due to Medical Error: A Perspective From Patient Advocates.

Kavanagh KT, Saman DM, Bartel R, Westerman K.

J Patient Saf. 2017 Mar;13(1):1-5. doi: 10.1097/PTS.0000000000000364.

PMID:
28187011
2.

The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness.

Delaney JW, Pinto R, Long J, Lamontagne F, Adhikari NK, Kumar A, Marshall JC, Cook DJ, Jouvet P, Ferguson ND, Griesdale D, Burry LD, Burns KE, Hutchison J, Mehta S, Menon K, Fowler RA; Canadian Critical Care Trials Group H1N1 Collaborative..

Crit Care. 2016 Mar 30;20:75. doi: 10.1186/s13054-016-1230-8.

3.

Middle fossa approach: Applications in temporal bone lesions.

Domenech Juan I, Cruz Toro P, Callejo Castillo Á, Moya R, Merán Gil JL, Bartel R.

Acta Otorrinolaringol Esp. 2016 Jul-Aug;67(4):233-8. doi: 10.1016/j.otorri.2015.06.001. Epub 2015 Dec 10. English, Spanish.

4.

Therapeutic potential of ixmyelocel-T, an expanded autologous multicellular therapy for treatment of ischemic cardiovascular diseases.

Ledford KJ, Murphy N, Zeigler F, Bartel RL, Tubo R.

Stem Cell Res Ther. 2015 Mar 13;6:25. doi: 10.1186/s13287-015-0007-3.

5.

Admission of the very elderly to the intensive care unit: family members' perspectives on clinical decision-making from a multicenter cohort study.

Heyland DK, Dodek P, Mehta S, Cook D, Garland A, Stelfox HT, Bagshaw SM, Kutsogiannis DJ, Burns K, Muscedere J, Turgeon AF, Fowler R, Jiang X, Day AG; Canadian Critical Care Trials Group and Canadian Researchers at End of Life Network (CARENET)..

Palliat Med. 2015 Apr;29(4):324-35. doi: 10.1177/0269216314566060. Epub 2015 Feb 2.

PMID:
25645668
6.

Contextualized analysis of a needs assessment using the Theoretical Domains Framework: a case example in endocrinology.

Lazure P, Bartel RC, Biller BM, Molitch ME, Rosenthal SM, Ross JL, Bernsten BD, Hayes SM.

BMC Health Serv Res. 2014 Jul 24;14:319. doi: 10.1186/1472-6963-14-319.

7.

Extreme heterogeneity in parasitism despite low population genetic structure among monarch butterflies inhabiting the Hawaiian Islands.

Pierce AA, de Roode JC, Altizer S, Bartel RA.

PLoS One. 2014 Jun 13;9(6):e100061. doi: 10.1371/journal.pone.0100061. eCollection 2014.

8.

Glutamine and antioxidants in the critically ill patient: a post hoc analysis of a large-scale randomized trial.

Heyland DK, Elke G, Cook D, Berger MM, Wischmeyer PE, Albert M, Muscedere J, Jones G, Day AG; Canadian Critical Care Trials Group..

JPEN J Parenter Enteral Nutr. 2015 May;39(4):401-9. doi: 10.1177/0148607114529994. Epub 2014 May 5.

PMID:
24803474
9.

Greater migratory propensity in hosts lowers pathogen transmission and impacts.

Hall RJ, Altizer S, Bartel RA.

J Anim Ecol. 2014 Sep;83(5):1068-77. doi: 10.1111/1365-2656.12204. Epub 2014 Mar 6.

10.

Potential beneficial effects of ixmyelocel-T in the treatment of atherosclerotic diseases.

Ledford KJ, Murphy N, Zeigler F, Bartel RL.

Stem Cell Res Ther. 2013 Nov 1;4(6):135. doi: 10.1186/scrt346.

11.

Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages.

Ledford KJ, Zeigler F, Bartel RL.

Stem Cell Res Ther. 2013 Nov 1;4(6):134. doi: 10.1186/scrt345.

12.

Acute kidney injury among critically ill patients with pandemic H1N1 influenza A in Canada: cohort study.

Bagshaw SM, Sood MM, Long J, Fowler RA, Adhikari NK; Canadian Critical Care Trials Group H1N1 Collaborative..

BMC Nephrol. 2013 Jun 13;14:123. doi: 10.1186/1471-2369-14-123.

13.

From bench to bedside: review of gene and cell-based therapies and the slow advancement into phase 3 clinical trials, with a focus on Aastrom's Ixmyelocel-T.

Bartel RL, Booth E, Cramer C, Ledford K, Watling S, Zeigler F.

Stem Cell Rev. 2013 Jun;9(3):373-83. doi: 10.1007/s12015-013-9431-x. Review.

14.

Stem cell therapy for craniofacial bone regeneration: a randomized, controlled feasibility trial.

Kaigler D, Pagni G, Park CH, Braun TM, Holman LA, Yi E, Tarle SA, Bartel RL, Giannobile WV.

Cell Transplant. 2013;22(5):767-77.

15.

The Aastrom experience.

Bartel RL, Cramer C, Ledford K, Longcore A, Parrish C, Stern T, Watling S, Zeigler F.

Stem Cell Res Ther. 2012 Jul 9;3(4):26. doi: 10.1186/scrt117. Review.

16.

Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial.

Powell RJ, Marston WA, Berceli SA, Guzman R, Henry TD, Longcore AT, Stern TP, Watling S, Bartel RL.

Mol Ther. 2012 Jun;20(6):1280-6. doi: 10.1038/mt.2012.52. Epub 2012 Mar 27.

17.

Bone repair cells for craniofacial regeneration.

Pagni G, Kaigler D, Rasperini G, Avila-Ortiz G, Bartel R, Giannobile WV.

Adv Drug Deliv Rev. 2012 Sep;64(12):1310-9. doi: 10.1016/j.addr.2012.03.005. Epub 2012 Mar 10. Review.

18.

Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia.

Powell RJ, Comerota AJ, Berceli SA, Guzman R, Henry TD, Tzeng E, Velazquez O, Marston WA, Bartel RL, Longcore A, Stern T, Watling S.

J Vasc Surg. 2011 Oct;54(4):1032-41. doi: 10.1016/j.jvs.2011.04.006. Epub 2011 Jul 31.

19.

Monarch butterfly migration and parasite transmission in eastern North America.

Bartel RA, Oberhauser KS, De Roode JC, Altizer SM.

Ecology. 2011 Feb;92(2):342-51.

PMID:
21618914
20.

Animal migration and infectious disease risk.

Altizer S, Bartel R, Han BA.

Science. 2011 Jan 21;331(6015):296-302. doi: 10.1126/science.1194694. Review.

PMID:
21252339

Supplemental Content

Loading ...
Support Center